-
Published08/07/2025
-
Deadline09/07/2025
-
Today09/07/2025
Utilities
Développement d'un inhibiteur pour une nouvelle cible thérapeutique (Hit to lead)
Note: Not all information for this procedure were successfully computed. Please consult linked documents for more details.
We seek to develop an inhibitor against a newly identified therapeutic target in our laboratory. Our focus will be on a chemical series derived from HTS screening, which has subsequently been optimized during a hit expansion phase. This request for proposal (RFP) concerns a hitto-lead optimization phase, which is expected to last for six months. The goal is to strengthen the structure-activity relationship (SAR) of our chemical series.
https://unicancer.e-marchespublics.com/pack/annonce_marche_public_10616_1098696.html
https://unicancer.e-marchespublics.com/pack/annonce_marche_public_10616_1098696.html
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.